Delegation from United Kingdom Royal College of Defense Studies (RCDS) headed by Air Commodore Steve Abbott and Colonel Darrel Amison, visited the state-of-the-art manufacturing facility of Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”) at Tongi on 26th May 2013, a company statement said today. He was accompanied by Lt. Col. Stuart Cattermull, Defense Advisor of the British High Commission of Dhaka.
Beximco Pharmaceuticals Limited (“BPL” or “the Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has commenced export of Company products to Europe.
Initially shipments of two ophthalmic products, Latanoprost and a combination of Latanoprost and Timolol, will be exported to Germany and Austria with other EU countries to follow. Latanoprost and Timolol are used to reduce the pressure inside the eye for people with open-angle glaucoma or intraocular hypertension (increased pressure in the eye). The Company expects to launch additional new products in the EU later this year.
Beximco Pharmaceuticals Ltd. is always committed to serving the medical community with innovative and academic services. The Company’s latest move was to equip the vision team task force with tablets - mobiles computers with touchscreen and pen-anabled interface – for the purpose of “pharmaceutical detailing”. This maneuver will not only keep the busy physicians uptodate about recent advances in medical science with prompt and quality services, this will help promote environmental awareness by reducing use of papers where practicable. The medical representatives can instantly pull up whatever references a doctor may wish to study. From the comfort of their own desks, doctors will now have the option of taking a tour in Beximco Pharma’s Ophthalmic manufacturing facility; which incidentally is the country’s one and only facility to have been awarded with Australian and European GMP (Good Manufacturing Practices) accreditations. This contemporary tactic is a first for Bangladesh.
Beximco Pharmaceuticals Limited (“Beximco Pharma” or the “Company”) has joined Mobile Alliance for Maternal Action (MAMA) in Bangladesh, an innovative coalition to use mobile phones for delivering life-saving health information to expectant and new mothers in Bangladesh. The Company has signed an agreement with D.Net, a social enterprise and the Coalition Coordinator of the MAMA initiative, at a simple ceremony held at Beximco Pharma’s Corporate Office on July 19, 2011. Ministry of Health and Family Welfare (MoHFW) and Access to Information (A2I) Programme at Prime Minister's Office are official partners of the initiative.
Beximco Pharmaceuticals Limited (“BPL” or “the Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids, today announces that it has received GMP (“Good Manufacturing Practices”) accreditation from the Regulatory Authority of Austria for its oral solid (tablets and capsules) and sterile eye drop facilities at Tongi, Dhaka. The approval received from the Austrian Drug Authority will be recognized throughout the European Union (EU) by Mutual Recognition between the member countries. This is a significant milestone for the company which should facilitate exports to the lucrative generic drug markets of Europe.
Leading drug manufacturer Beximco Pharmaceuticals Ltd. (BPL) yesterday (September 13, 2009) donated 5000 pcs. of Oseflu (Oseltamivir) capsule to ICDDR,B as a gesture of BPL’s support for the swine flu affected community of the country. This donation was a part of BPL’s ongoing CSR activities as a response to this major public health problem.
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading Bangladeshi pharmaceutical manufacturer and largest pharmaceutical exporter from Bangladesh, is pleased to announce that it has received GMP Certificate for its facility from National Health Surveillance Agency (Anvisa) of Brazil. BPL is the first Bangladeshi company to receive this regulatory approval from Anvisa through a stringent facility audit process.
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”) today announces that it has commenced supplying Oseltamivir capsules, Oseflu® (BPL′s generic version of Tamiflu® ), to Latin and Central American countries, the regions most affected by the recent H1N1 swine flu (influenza A) outbreak.
In a meeting of the Board of Directors of Beximco Pharmaceuticals Ltd (“BPL” or the “Company”) held on 7th May 2009 Mr. Nazmul Hassan was appointed Managing Director of the Company.